Brokers Issue Forecasts for KYMR FY2029 Earnings

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Analysts at Brookline Capital Management issued their FY2029 earnings estimates for shares of Kymera Therapeutics in a research note issued on Monday, January 6th. Brookline Capital Management analyst L. Cann forecasts that the company will post earnings per share of ($6.44) for the year. The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.79) per share.

A number of other research analysts have also weighed in on the company. Truist Financial reissued a “buy” rating and set a $53.00 price target (down previously from $54.00) on shares of Kymera Therapeutics in a research note on Friday, November 1st. BTIG Research initiated coverage on shares of Kymera Therapeutics in a report on Tuesday, December 10th. They set a “buy” rating and a $60.00 price objective on the stock. Wells Fargo & Company upgraded shares of Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $38.00 to $57.00 in a report on Monday, December 2nd. UBS Group dropped their price objective on Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating for the company in a report on Monday, November 4th. Finally, BMO Capital Markets initiated coverage on Kymera Therapeutics in a report on Friday, December 6th. They issued a “market perform” rating and a $55.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $55.38.

Kymera Therapeutics Stock Performance

Shares of NASDAQ KYMR opened at $40.52 on Wednesday. The firm has a market cap of $2.62 billion, a P/E ratio of -17.32 and a beta of 2.19. Kymera Therapeutics has a 1 year low of $25.46 and a 1 year high of $53.27. The firm’s 50 day moving average price is $44.20 and its 200 day moving average price is $43.92.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.01. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business had revenue of $3.74 million during the quarter, compared to analysts’ expectations of $10.34 million. During the same quarter last year, the business posted ($0.90) earnings per share. The business’s revenue for the quarter was down 20.9% on a year-over-year basis.

Insider Buying and Selling

In other news, insider Ellen Chiniara sold 3,129 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $41.75, for a total transaction of $130,635.75. Following the completion of the transaction, the insider now owns 54,826 shares in the company, valued at approximately $2,288,985.50. This represents a 5.40 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 15.82% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of KYMR. Bank of New York Mellon Corp boosted its holdings in shares of Kymera Therapeutics by 19.3% in the second quarter. Bank of New York Mellon Corp now owns 156,211 shares of the company’s stock valued at $4,663,000 after acquiring an additional 25,317 shares in the last quarter. Rhumbline Advisers boosted its stake in Kymera Therapeutics by 12.4% during the 2nd quarter. Rhumbline Advisers now owns 64,535 shares of the company’s stock valued at $1,926,000 after purchasing an additional 7,143 shares in the last quarter. Arizona State Retirement System increased its position in shares of Kymera Therapeutics by 15.6% during the 2nd quarter. Arizona State Retirement System now owns 12,830 shares of the company’s stock valued at $383,000 after purchasing an additional 1,730 shares during the period. Quest Partners LLC lifted its holdings in shares of Kymera Therapeutics by 1,402.0% in the second quarter. Quest Partners LLC now owns 5,212 shares of the company’s stock valued at $156,000 after buying an additional 4,865 shares during the period. Finally, Massachusetts Financial Services Co. MA boosted its stake in Kymera Therapeutics by 2.7% during the second quarter. Massachusetts Financial Services Co. MA now owns 405,870 shares of the company’s stock valued at $12,115,000 after buying an additional 10,731 shares in the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.